CXCR4 and ovarian carcinoma: Recently, Yin and Qian (2021) (125) showed enhanced anti-tumor activity after treatment with anti-CD44v6 MWNTS, carrying CXCR4 and either gemcitabine or oxaliplatin, in in vitro and in vivo models of ovarian cancer, whereas Andrade et al.